Trial Condition(s):

Deep vein thrombosis (DVT), pulmonary embolism (PE)

Treatment of venous thromboembolism (VTE) with either rivaroxaban or current standard of care therapy (XALIA LEA)

Bayer Identifier:

17237

ClinicalTrials.gov Identifier:

NCT02210819

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for patients with acute venous thoromboembolism (VTE).
The main goal is to analyze long-term safety in the use of rivaroxaban in the treatment of acute VTE in routine clinical practice.

Inclusion Criteria
-  Female or male patients, who are at >=18 years
 -  Diagnosis of acute DVT and/or PE, objectively confirmed
 -  Indication for anticoagulation therapy for at least 12 weeks
 -  Willing to participate in this study and available for follow-up
Exclusion Criteria
-  Exclusion criteria must be read in conjunction with the local product information.

Trial Summary

Enrollment Goal
1987
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Mexico

Status
Completed
 
Locations

Investigative Site

Many Locations, Turkey

Status
Terminated
 
Locations

Investigative Site

Many Locations, Russia

Status
Completed
 
Locations

Investigative Site

Many Locations, South Korea

Status
Completed
 
Locations

Investigative Site

Many Locations, Taiwan, China

Status
Completed
 
Locations

Investigative Site

Many Locations, Malaysia

Status
Completed
 
Locations

Investigative Site

Many Locations, Philippines

Status
Completed
 
Locations

Investigative Site

Many Locations, Singapore

Status
Completed
 
Locations

Investigative Site

Many Locations, Egypt

Status
Completed
 
Locations

Investigative Site

Many Locations, Saudi Arabia

Status
Completed
 
Locations

Investigative Site

Many Locations, Kuwait

Status
Terminated
 
Locations

Investigative Site

Many Locations, Jordan

Status
Completed
 
Locations

Investigative Site

Many Locations, Lebanon

Status
Completed
 
Locations

Investigative Site

Many Locations, Qatar

Status
Terminated
 
Locations

Investigative Site

Many Locations, United Arab Emirates

Status
Terminated
 
Locations

Investigative Site

Many Locations, Kenya

Status
Completed
 
Locations

Investigative Site

Many locations, Indonesia

Status
Completed
 
Locations

Investigative Site

Many locations, Kazakhstan

Status
Completed
 
Locations

Investigative Site

Many locations, Ukraine

Status
Completed
 
Locations

Investigative Site

Many locations, Algeria

Status
Completed
 
Locations

Investigative Site

Many Locations, Morocco

Status
Terminated
 

Trial Design